Dr. Rolsma has experience in microbiology, vaccine development, and clinical research, and her current research focuses on therapeutics and interventions in critically-ill patients and clinical trials.

She is currently leading studies to evaluate the utility of therapeutic drug monitoring of beta-lactam antibiotics in critically-ill pediatric and adult patients, including patients receiving intensive cardiac support and renal replacement therapy; to evaluate the safety, immunogenicity, and efficacy of SARS-CoV-2 vaccines in adults and children; and to evaluate the safety and immunogenicity of an intranasal influenza vaccine in children.

Dr. Rolsma also works to address vaccine safety issues as part of the CDC Clinical Immunization Safety Assessment Project.

Dr. Carroll is a clinical and health services researcher. She is a AHRQ T32 Patient/pRactice Outcomes and Research in Effectiveness and Systems Science (PROgRESS) scholar and has received a Novice Research Grant from the Gerber Foundation to help support her current research on health literacy and discharge medication counseling which includes a randomized controlled trial to assess the efficacy of a health literacy-informed communication intervention to reduce discharge medication errors in infants and young children. Dr. Carroll plans to submit a career development award which will focus on utilizing implementation science to reduce disparities in clinical outcomes for children hospitalized with lower respiratory tract infections.

>> View Publications on PubMed

During graduate school, Dr. Schuler utilized whole exome and whole genome sequencing to identify genetic changes that could be responsible for undiagnosed genetic disorders in multiple families followed by experimental approaches to causally link those genetic changes with disease. He continues to have an interest in improving our ability to increase the efficiency and accuracy of diagnosing genetic disease. His work focuses on the utilization of biomedical informatics approaches, biobanked DNA, and electronic health record data to identify undiagnosed genetic disease. The goal of this work is to expand our knowledge of phenotypic associations, recognize clinical patterns, and identify ways to improve diagnosis and management of genetic disease.

We are leveraging a large DNA biobank coupled with EHR data to identify patterns of undiagnosed genetic disease. Our work has confirmed the previously reported, disproportionately high proportion of critically ill neonates with an underlying genetic contribution to their illness, that there is an underdiagnosis of these disorders, and that there are means that we can improve application of genetic testing approaches. We are working to identify early developmental phenotypic presentations of genetic disease in critically ill neonates to decrease the morbidity and mortality of this patient population by earlier diagnosis and informed management.

>> View Publications on PubMed

Dr. Klein’s research focuses on developing and implementing targeted nutritional interventions to prevent and treat malnutrition across the lifespan in people with sickle cell disease in low- and high-income settings. While a Vanderbilt Pediatric Gastroenterology, Hepatology, and Nutrition fellow, her research program was supported by the Training in Gastroenterology T32. She also completed a Vanderbilt-Emory-Cornell Duke Fogarty Global Health fellowship in Accra, Ghana, west Africa, focused on the risk factors for low birth weight in infants born from mothers with sickle cell disease. During her fellowship, she helped lead a randomized controlled trial for children with sickle cell disease and severe acute malnutrition in Nigeria. Dr. Klein plans to submit a career development award to build upon this work to improve the treatment of children with sickle cell disease and malnutrition.

>> View Publications on PubMed